TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9543160

Group type: EXPERIMENTAL
Intervention: Deep abdominal fat area
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Subcutaneous abdominal fat area
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Total body fat
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Waist to hip ratio
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plasma triglyceride concentrations
Number of subjects: 21
Study: 8304607

Group type: EXPERIMENTAL
Intervention: 2 mg aerosolized glycopyrrolate
Number of subjects: 125

Group type: COMPARATOR
Intervention: Aerosolized placebo (control)
Number of subjects: 125
Study: 2723098

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration procedure with muco-periosteal flap elevation, granulation tissue removal, root surface debridement, and placement of a teflon membrane.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control surgical procedure identical to the test procedure without the placement of membranes.
Number of subjects: 21
Study: 31022593

Group type: EXPERIMENTAL
Intervention: Spaced Prolonged Exposure (S-PE)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Massed Prolonged Exposure (M-PE)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Present Centered Therapy (PCT)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Minimal Contact Control (MCC)
Number of subjects: 335
Study: 29183930

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.1%) solution for meatal cleaning prior to catheter insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 25439116

Group type: EXPERIMENTAL
Intervention: Standard care with adjunct intervention (guided imagery/relaxation exercises DVD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 23224788

Group type: EXPERIMENTAL
Intervention: 80 mg aprepitant
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 125 mg aprepitant
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study: 21332630

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg
Number of subjects: 4844

Group type: EXPERIMENTAL
Intervention: Combined therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Number of subjects: 4844

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 4844
Study: 19502544

Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Rapid-acting insulin analogs (RAIA)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 113

Group type: COMPARATOR
Intervention: RAIA
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study: 16988169

Group type: EXPERIMENTAL
Intervention: Valdecoxib, 40 mg with a 20-mg redose (n = 127)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Valdecoxib, 40 mg with a placebo redose (n = 122)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Placebo/placebo (n = 125)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Valdecoxib, 20 mg twice daily (n = 160)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Valdecoxib, 20 mg once daily (n = 159)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Placebo (n = 159)
Number of subjects: 852
Study: 14976881

Group type: EXPERIMENTAL
Intervention: Qinggan Huoxue recipe (QGHXR)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Xiaochaihu granule (XCHG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 120
Study: 11083138

Group type: EXPERIMENTAL
Intervention: Interval test on a cycle ergometer
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Field test with dynamic leg exercises
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Interval wheelchair test on a motor driven treadmill
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Wheelchair field test with dynamic and static arm exercise
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Field test with nursing tasks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Field test with low and high physiological strain
Number of subjects: 62
Study: 9022874

Group type: EXPERIMENTAL
Intervention: Measure of susceptibility to smoking (lack of a firm commitment not to smoke)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Measure of susceptibility to smoking
Number of subjects: 687
Study: 8633187

Group type: EXPERIMENTAL
Intervention: felodipine 5 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 2568838

Group type: EXPERIMENTAL
Intervention: bopindolol (0.05 mg, 0.5 mg, 1 mg, 2 mg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: nifedipine (2 x 20 mg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: bopindolol
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: bopindolol and nifedipine
Number of subjects: 203
Study: 368770

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (Decadurabolin)
Number of subjects: 27
Study: 31378394

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg oral, hourly, with dose escalation)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg oral, hourly, with dose escalation)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Methyldopa (1000 mg oral, single dose, no escalation)
Number of subjects: 894
Study: 27897406

Group type: EXPERIMENTAL
Intervention: High-level care (HLC)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Low-level care (LLC)
Number of subjects: 289
Study: 27234199

Group type: EXPERIMENTAL
Intervention: PTSD treatment participation
Number of subjects: 146
Study: 23619700

Group type: EXPERIMENTAL
Intervention: Motor Imagery Training (MIT) 30-min, 5 days/week for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Rehabilitation Therapy (CRT) 5 days/week for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (MIT and CRT)
Number of subjects: 18
Study: 21765808

Group type: EXPERIMENTAL
Intervention: Spot-spot-morning (SSM) scheme
Number of subjects: 6627

Group type: COMPARATOR
Intervention: Standard spot-morning-spot (SMS) scheme
Number of subjects: 6627

Group type: EXPERIMENTAL
Intervention: Spot-spot (first two smears of SSM)
Number of subjects: 6627

Group type: COMPARATOR
Intervention: Spot-morning (first two smears of SMS)
Number of subjects: 6627

Group type: EXPERIMENTAL
Intervention: SSM scheme
Number of subjects: 6627

Group type: COMPARATOR
Intervention: SMS scheme
Number of subjects: 6627
Study: 19212122

Group type: EXPERIMENTAL
Intervention: Metformin treatment for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: PCOS women
Number of subjects: 48
Study: 16648506

Group type: EXPERIMENTAL
Intervention: Oral uracil and tegafur (UFT) plus leucovorin (LV)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Intravenous fluorouracil (FU) plus leucovorin (LV)
Number of subjects: 1608
Study: 15612616

Group type: EXPERIMENTAL
Intervention: Test formulation of fluconazole 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of fluconazole 200 mg
Number of subjects: 24
Study: 11352452

Group type: EXPERIMENTAL
Intervention: Tefilcon contact lenses
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vifilcon contact lenses
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Total lipid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triolein (largest lipid extracted)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Smaller lipids
Number of subjects: 8
Study: 8919737

Group type: EXPERIMENTAL
Intervention: VIDAS enzyme linked fluorescent assay
Number of subjects: 430

Group type: COMPARATOR
Intervention: Chlamydiazyme
Number of subjects: 430

Group type: COMPARATOR
Intervention: Polymerase chain reaction
Number of subjects: 430
Study: 1920229

Group type: EXPERIMENTAL
Intervention: Feeding after 4 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Feeding after 18 hours
Number of subjects: 100
Study: 6195795

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for advanced and metastatic bladder carcinomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local chemotherapy (doxorubicin) for carcinoma in situ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy after complete transurethral resection of superficial bladder tumors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy following radical surgery or radiotherapy
Number of subjects: 0
Study: 30712728

Group type: EXPERIMENTAL
Intervention: Inhalation of 3 drops of 4% rose essential oil for 10 minutes one night and one hour before surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 27874971

Group type: EXPERIMENTAL
Intervention: Cefiderocol 1000 mg intravenous infusion
Number of subjects: 0
Study: 25684224

Group type: COMPARATOR
Intervention: Levetiracetam (LEV)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Controlled-released carbamazepine (CR-CBZ)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 359
Study: 24647908

Group type: EXPERIMENTAL
Intervention: Inhomogeneous static magnetic field (SMF) exposure for 30 minutes after RWPE challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated SMF exposure (on 3 consecutive days) after RWPE challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged SMF exposure (60 minutes) after RWPE challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMF exposure
Number of subjects: 0
Study: 22568738

Group type: EXPERIMENTAL
Intervention: Suburban Area (SA) adolescents
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Downtown Area (DA) adolescents
Number of subjects: 332
Study: 19944392

Group type: EXPERIMENTAL
Intervention: Intravenous hydration (1000mL of 0.9% saline infusion)
Number of subjects: 201

Group type: COMPARATOR
Intervention: No additional hydration (control group)
Number of subjects: 201
Study: 18158690

Group type: EXPERIMENTAL
Intervention: 400 mg of vitamin E
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1000 mg of vitamin C
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg of vitamin E and 1000 mg of vitamin C
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14693597

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg followed by cisatracurium 0.03 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cisatracurium 0.15 mg/kg followed by cisatracurium 0.03 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg followed by rocuronium 0.15 mg/kg
Number of subjects: 60
Study: 11858491

Group type: EXPERIMENTAL
Intervention: Ximelagatran (60 mg p.o.)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg s.c.)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (water p.o.)
Number of subjects: 54
Study: 9400450

Group type: EXPERIMENTAL
Intervention: Alprostadil alpha‐cyclodextrin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Moxisylyte chlorhydrate
Number of subjects: 156
Study: 9375234

Group type: EXPERIMENTAL
Intervention: Left hemisphere (LH) stimulation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Right hemisphere (RH) stimulation
Number of subjects: 14
Study: 2193712

Group type: EXPERIMENTAL
Intervention: Inderal LA 160 mg daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Half-Inderal LA 80 mg daily
Number of subjects: 51
Study: 454094

Group type: EXPERIMENTAL
Intervention: Marijuana (6 mg of delta‐9‐tetrahydrocannabinol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31768868

Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 278

Group type: COMPARATOR
Intervention: LSG
Number of subjects: 278
Study: 31289281

Group type: EXPERIMENTAL
Intervention: Cefaly device
Number of subjects: 100
Study: 27070868

Group type: EXPERIMENTAL
Intervention: Method of Amplification of Error (MAE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Direct Instruction (DI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 25966363

Group type: EXPERIMENTAL
Intervention: Exercise training (12-week supervised program, 5 days/week, 1 h/day, 80-85% of maximum heart rate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 24
Study: 24020372

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nutrient restriction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 21843084

Group type: EXPERIMENTAL
Intervention: Gordonia bronchialis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhodococcus coprophilus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19689921

Group type: EXPERIMENTAL
Intervention: Modafinil (up to 300 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 17381567

Group type: EXPERIMENTAL
Intervention: Jugular vein compression during epidural catheter placement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Jugular vein compression after catheter withdrawal
Number of subjects: 20
Study: 15502050

Group type: EXPERIMENTAL
Intervention: PTX 5 mg/kg IV infusion before anesthesia induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study: 11436936

Group type: EXPERIMENTAL
Intervention: Message Group
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 266
Study: 9143068

Group type: EXPERIMENTAL
Intervention: Supervised weight-training program three times a week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 32
Study: 8203209

Group type: EXPERIMENTAL
Intervention: Random dot pattern (ROKN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wide interval stripe pattern (SOKN)
Number of subjects: 30
Study: 3102858

Group type: EXPERIMENTAL
Intervention: AS-1-preserved erythrocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 0
Study: 28987470

Group type: EXPERIMENTAL
Intervention: ω‐3 long chain‐PUFA (2.9 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 36
Study: 27751832

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneal pressure (PP) of 6-8 mmHg (Group I)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pneumoperitoneal pressure (PP) of 9-10 mmHg (Group II)
Number of subjects: 46
Study: 25693783

Group type: EXPERIMENTAL
Intervention: Ixekizumab 25 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ixekizumab 75 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ixekizumab 150 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ixekizumab (all doses) in OLE at week 48
Number of subjects: 142
Study: 22147903

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe combination
Number of subjects: 1533
Study: 19077131

Group type: EXPERIMENTAL
Intervention: Fluoxetine or venlafaxine (n = 30)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 58
Study: 17229251

Group type: EXPERIMENTAL
Intervention: Volunteer-mediated intervention (daily orientation, therapeutic activities, feeding and hydration assistance, vision and hearing protocols)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 37
Study: 15764421

Group type: EXPERIMENTAL
Intervention: Tryptophan + contingent vouchers
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Tryptophan + non-contingent vouchers
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo + contingent vouchers
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo + non-contingent vouchers
Number of subjects: 199
Study: 11913803

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 100
Study: 9440743

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant external-beam radiation therapy (XRT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Surgery alone (Control group for low-grade lesions)
Number of subjects: 141
Study: 8206471

Group type: EXPERIMENTAL
Intervention: Prophylactic clotrimazole 500 mg ovule just before or on the last day of the menses each month for 6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Empiric self-treatment with clotrimazole 500 mg ovule at the onset of symptoms for 6 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Prophylactic clotrimazole
Number of subjects: 23

Group type: COMPARATOR
Intervention: Empiric self-treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patient preference for regimen
Number of subjects: 23
Study: 2914540

Group type: EXPERIMENTAL
Intervention: Sennosides (30 mg orally at 7:00 PM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 7
Study: 4736626

Group type: EXPERIMENTAL
Intervention: Stilboestrol 1 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stilboestrol 7.5 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stilboestrol 15 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens (Premarin) 15 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Various oestrogen regimens
Number of subjects: 16
Study: 31974099

Group type: EXPERIMENTAL
Intervention: Rapid insulin-and-pramlintide artificial pancreas
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Regular insulin-and-pramlintide artificial pancreas
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rapid insulin-alone artificial pancreas
Number of subjects: 112
Study: 31776293

Group type: EXPERIMENTAL
Intervention: PF‐06427878 1500 milligrams per day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 63
Study: 30014661

Group type: EXPERIMENTAL
Intervention: Moxibustion combined with 5‐HT receptor antagonist
Number of subjects: 58

Group type: COMPARATOR
Intervention: 5‐HT receptor antagonist (control group)
Number of subjects: 58
Study: 27135149

Group type: EXPERIMENTAL
Intervention: Prednisolone (moderately high dose), starting at least six hours pre-PCI and continued for 28 days post-PCI
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Cobalt chromium (CoCr) alloy stents
Number of subjects: 315

Group type: COMPARATOR
Intervention: Stainless steel (SS) alloy stents
Number of subjects: 315
Study: 24354833

Group type: EXPERIMENTAL
Intervention: Durham Connects (intervention)
Number of subjects: 4777
Study: 22992074

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 6026

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 6026

Group type: COMPARATOR
Intervention: No hypoglycemia
Number of subjects: 6026

Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia (>1 day)
Number of subjects: 6026

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia without insulin treatment
Number of subjects: 6026

Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia
Number of subjects: 6026

Group type: EXPERIMENTAL
Intervention: Death from distributive shock
Number of subjects: 6026
Study: 19927026

Group type: EXPERIMENTAL
Intervention: Quercetin (Q; 1000 mg x d(‐1))
Number of subjects: 26
Study: 17115179

Group type: EXPERIMENTAL
Intervention: Nonexercise prediction models using thigh skeletal muscle mass and cardiac dimensions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nonexercise prediction models using left ventricular internal dimensions and stroke volume
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nonexercise prediction models applied to the validation group
Number of subjects: 60
Study: 16293869

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel 35 mg/m2 on days 1, 8, and 15 for < or = eight cycles
Number of subjects: 215

Group type: COMPARATOR
Intervention: 3‐weekly docetaxel 75 mg/m2 on day 1 every 3 weeks for < or = eight cycles
Number of subjects: 215
Study: 11916776

Group type: EXPERIMENTAL
Intervention: HBOC‐201 (0.6, 0.9, 1.2, 1.5, 2.0, or 2.5 g/kg of body weight)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: HBOC‐201
Number of subjects: 81
Study: 9588719

Group type: EXPERIMENTAL
Intervention: 1 cm margin of resection for melanomas up to 2 mm thick
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 cm margin of resection for melanomas 1 to 4 mm thick
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 cm margin of resection for melanomas thicker than 4 mm
Number of subjects: 0
Study: 7639505

Group type: EXPERIMENTAL
Intervention: Enalapril + Hydrochlorothiazide (20 mg/12.5 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Captopril + Hydrochlorothiazide (50 mg/25 mg)
Number of subjects: 26
Study: 2666455

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 736633

Group type: EXPERIMENTAL
Intervention: EE2 (0.25 mg starting dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: E3 (2 mg starting dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: E3-suc (2.5 mg starting dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EE2 followed by E3 or E3-suc
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilirubin
Number of subjects: 30
Study: 31492643

Group type: EXPERIMENTAL
Intervention: Therapist-delivered telephone CBT
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Web-based CBT with minimal therapist support
Number of subjects: 558

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 558
Study: 30033974

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVFX) 500 mg
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Sitafloxacin (STFX)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Comparison of LVFX and STFX
Number of subjects: 411
Study: 26360083

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) intervention, 6 sessions over 8 weeks added to standard care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 150